Skip to main content
All lobbying filings

MEHLMAN CONSULTING, INC.

MEHLMAN CONSULTING, INC. filed a Q3 report for THE CAMPAIGN FOR SUSTAINABLE RX PRICING on October 17, 2025, reporting $90,000 in lobbying income.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

All filings by MEHLMAN CONSULTING, INC. · Everything THE CAMPAIGN FOR SUSTAINABLE RX PRICING has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 17, 2025
Income
$90,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • JOSEPH EDWARD BROWN III New on this filing
    Previously held: Sr Prof Staff (EPW Comm Maj/Sen. Moore Capito); Prof Staff (EPW Comm Min/Ranking Mem Sen. Moore Capito); Leg Asst (Sen. Boozman); Maj Leg Asst (EPW Comm Maj/Sen. Jim Inhofe); Maj Research Asst (EPW Comm Maj/Sen. Jim Inhofe); Intern (Rep. Jim Renacci)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1/PL 119-21 - One Big Beautiful Bill Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 1067 - Ensuring Timely Access to Generics Act; S. 2630 - REMEDY Act

Copyright/Patent/Trademark

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act. S. 2658 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.

 Bills named in this filing 23
  • S. 229
    DTC Act of 2025
  • H.R. 3789
    DTC Act of 2025
  • H.R. 1
    One Big Beautiful Bill Act
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1032
    Major Richard Star Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • S. 1095
    Stop STALLING Act
  • S. 1067
    Ensuring Timely Access to Generics Act of 2023
  • S. 2630
    Saving NSF’s Workforce Act
  • S. 1040
    Drug Competition Enhancement Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • S. 43
    Skinny Labels, Big Savings Act
  • H.R. 3269
    ETHIC Act
  • S. 2276
    ETHIC Act
  • S. 2658
    Medication Affordability and Patent Integrity Act
  • H.R. 3160
    PREVAIL Act
  • S. 1533
    A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
  • H.R. 3152
    Patent Eligibility Restoration Act of 2025
  • S. 1546
    Patent Eligibility Restoration Act of 2025
  • H.R. 3010
    No Handouts for Drug Advertisements Act
  • S. 1785
    No Handouts for Drug Advertisements Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem